This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It’s usually dispensed in pharmacies as a genericmedicine, but healthcare providers commonly refer to it by brand names Flexeril (immediate-release tablets), Fexmid (immediate-release tablets), or Amrix (extended-release capsules). Cyclobenzaprine is a prescription muscle relaxant that is approved by the U.S. as a brand-name drug.
In 2022, the Executive Steering Group on Shortages and Safety of Medicinal Products was established to ensure a robust response to medicine supply issues caused by major events or public health emergencies. All of the results highlighted the far-reaching consequences of medicines shortages in daily practice.
in 2022 to 1% in 2023 due to the “tightening of monetary and financial conditions”. Furthermore, for months, several financial institutions such as Bank of America and JP Morgan have been talking of a “mild recession” in 2023 for the US. by the end of 2023 and may continue to rise in 2024 to 5%.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
2023 
52 
Let's personalize your content